NCT00496652View on ClinicalTrials.gov

DAHANCA 19: The Importance of the EGFr-inhibitor Zalutumumab for the Outcome After Curative Radiotherapy for HNSCC

PHASE3CompletedINTERVENTIONAL

Enrollment

619

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

July 31, 2012

Study Completion Date

November 30, 2016

Conditions

Cancer of the Head and Neck

Interventions

RADIATION

Radiotherapy

Radiotherapy 66-68 Gy, 2Gy/fx, 6 fx/week (+ weekly cisplatin 40 mg/m2 during radiotherapy to stage 3+4)

DRUG

Zalutumumab

Zalutumumab 8 mg/kg every week during radiotherapy + the week before start of radiotherapy (as loading dose)

Trial Locations (1)

8000 N

Department of Experimental Clinical Oncology, Aarhus University Hospital, Aarhus

All Listed Sponsors

lead

Danish Head and Neck Cancer Group

NETWORK

NCT00496652 - DAHANCA 19: The Importance of the EGFr-inhibitor Zalutumumab for the Outcome After Curative Radiotherapy for HNSCC | Biotech Hunter | Biotech Hunter